USU Home A-Z index calendars MyUSU contact people/web search
 

Department of Animal, Dairy and Veterinary Sciences
 

mugshot



John D. Morrey, PhD
 Research Professor


Utah State University
ADVS Department
4815 Old Main Hill
Logan UT 84322-4700

phone (435)797-2622
fax (435)797-2118
email jmorrey at cc.usu.edu

 
PRESENTATIONS AND ABSTRACTS
  1. Invited oral presentation. John D. Morrey. “Treatment of influenza-associated encephalitis”, at Development and Use of Antivirals for Pandemic Influenza, Bethesda, MD. November 8-9, 2006.


  2. Oral presentation. John D. Morrey. “Treatment of West Nile virus” at Collaborative Antiviral Testing Group Annual Contractor Meeting. Rockville, MD, April 25-27, 2006.


  3. Oral presentation. John D. Morrey. “Treatment of prion disease” at Collaborative Antiviral Testing Group Annual Contractor Meeting. Rockville, MD, April 25-27, 2006.


  4. Oral presentation. John D. Morrey, Venkatraman Siddharthan, Aaron L. Olsen, Grant J. Roper, Thomas J. Baldwin, Scott Koenig, Syd Johnson, Jeffrey L. Nordstrom, Michael S. Diamond. “Treatment of West Nile disease with humanized monoclonal antibody after the virus is in the brain”, 19th International Conference on Antiviral Research, San Juan, Puerto Rico, Caribe Hilton Hotel, May 7 - 11, 2006.


  5. Oral presentation. John D. Morrey, Venkatraman Siddharthan, Aaron L. Olsen, Grant J. Roper, Thomas J. Baldwin, Scott Koenig, Syd Johnson, Jeffrey L. Nordstrom, Michael S. Diamond. “Treatment of West Nile disease with humanized monoclonal antibody after the virus is in the brain”, 7th International Symposium on NeuroVirology, May 31 – June 3, 2006 Philadelphia, PA.


  6. Poster presentation. Venkatraman Siddharthan, Grant J Roper, Wang Hong, Aaron L. Olsen, Landon Preece, Andrew Christensen, Brandon Taro, and John D. Morrey. “Identification of West Nile virus-infected cells in the central nervous system of rodents early in infection: Implications for treatment”, 19th International Conference on Antiviral Research, San Juan, Puerto Rico, Caribe Hilton Hotel, May 7 - 11, 2006.


  7. Poster presentation. Aaron L. Olsen, Venkatraman Siddharthan, Jeffrey O. Hall, John D. Morrey. “Transforming growth factor-b1 improves blood-brain barrier properties in mice infected with West Nile virus”, 19th International Conference on Antiviral Research, San Juan, Puerto Rico, Caribe Hilton Hotel, May 7 - 11, 2006.


  8. Poster presentation. Justin G. Julander, Kristiina Shafer, John D. Morrey, Lawrence Blatt, and Robert W. Sidwell. “Comparison of the inhibitory effects of ribavirin and interferon alfacon 1 on a yellow fever virus infection in Syrian golden hamsters”, 19th International Conference on Antiviral Research, San Juan, Puerto Rico, Caribe Hilton Hotel, May 7 - 11, 2006.


  9. Poster presentation. John D. Morrey, Aaron L. Olsen, Justin G. Julander, Robert W. Sidwell, Grant J. Roper, Michael R. Fetell. “Treatment of West Nile disease with neuroprotective agents”, 19th International Conference on Antiviral Research, San Juan, Puerto Rico, Caribe Hilton Hotel, May 7 - 11, 2006.


  10. Poster presentation. Venkatraman Siddharthan, Justin G. Julander, Wang Hong, Grant J. Roper, Aaron L. Olsen, John D. Morrey. Tropism of encephalitis-causing viruses in the central nervous system of rodents. 7th International Symposium on NeuroVirology, May 31 – June 3, 2006 Philadelphia, PA.


  11. John D. Morrey. “Therapeutic intervention of infectious brain diseases: West Nile virus, transmissible spongiform encephalopathy.” Invited oral presentation. 2005-2996 Distinguished Lecture Series, Emerging Infectious Diseases and Biodefense and Microbial Pathogenesis Seminar Series, University of Utah, Salt Lake City, UT, November 11, 2005.


  12. John D. Morrey. “Animal Models of Human Viral Infections for Evaluation of Experimental Therapies: Hepatitis B Virus” Oral presentation. Collaborative Antiviral Testing Group Annual Meeting. Rockville, MD, June 2, 2005.


  13. John D. Morrey. “Animal Models of Human Viral Infections for Evaluation of Experimental Therapies: West Nile virus” Oral presentation. Collaborative Antiviral Testing Group Annual Meeting. Rockville, MD, June 2, 2005.


  14. John D. Morrey. “Animal Models of Human Viral Infections for Evaluation of Experimental Therapies: Transmissible Spongiform Encephalopathies” Oral presentation. Collaborative Antiviral Testing Group Annual Meeting. Rockville, MD, June 2, 2005.


  15. A.L. Olsen, K. Shafer, D. Chen, R.W. Sidwell, John D. Morrey. “Presumptive identification of a protein associated with West Nile virus encephalitis in CSF of hamsters.” Poster presentation. 18th International Conference on Antiviral Research, Barcellona, Spain, April 11, 2005.


  16. John D. Morrey, D.A. Kocisko, R.E. Race, J. Chen, B. Caughey. “Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice.” Poster presentation. 18th International Conference on Antiviral Research, Barcellona, Spain, April 11, 2005.


  17. J.G. Julander, Q.A. Winger, P-Y. Shi, C.W. Day, A.L. Olsen, R.W. Sidwell, John D. Morrey. “Terminal Differentiation of Trophoblast Cells Serves as a Barrier to West Nile Virus Infection of the Fetus in Mice.“ Oral presentation. 18th International Conference on Antiviral Research, Barcellona, Spain, April 11, 2005.


  18. John D. Morrey, V. Siddharthan, D. Chen, T. Baldwin, M. Diamond, S. Koenig. “Treatment and disease markers for alpha and flaviviruses.” Oral presentation. RMRCE Annual Meeting, Ft. Collins, CO, October 4, 2005.


  19. John D. Morrey, Craig W. Day, Justin G. Julander, Aaron L. Olsen, Robert W. Sidwell, Carl D. Cheney, Lawrence M. Blatt. Modeling hamsters for evaluating West Nile virus therapies. ASM Biodefense Meeting, Baltimore, MD, May 7-10, 2004.


  20. John D. Morrey, Aaron L. Olsen, Robert W. Sidwell. Precise delivery of test agents in the lateral ventricular chamber of the brain in rodents to investigate the neurobiology of viruses. ASM Biodefense Meeting, Baltimore, MD, May 7-10, 2004.


  21. Aaron A. Olsen, John D. Morrey. Identification of Proteins Associated with West Nile Virus Encephalitis in the CSF of Hamsters. Keystone Symposium, Molecular Mechanisms of TSE Diseases/CNS Inflammation, January 11-15, 2005.


  22. Aaron L. Olsen, Kristiina Shafer, Dong Chen, Robert W. Sidwell, John D. Morrey. Presumptive identification of a protein associated with West Nile virus encephalitis in CSF of hamsters. 18th International Conference on Antiviral Research. April 10-14, 2005.


  23. Justin G. Julander , Quinton A. Winger , Pei-Yong Shi , Craig W. Day, Aaron L. Olsen , Robert W. Sidwell, and John D. Morrey. Terminal Differentiation of Trophoblast Cells Serves as a Barrier to West Nile Virus Infection of the Fetus in Mice. 18th International Conference on Antiviral Research. April 10-14, 2005.


  24. John D. Morrey, David A. Kocisko, Richard, E. Race, Byron Caughey. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. Keystone Symposium, Molecular Mechanisms of TSE Diseases/CNS Inflammation, January 11-15, 2005.


  25. John D. Morrey, David A. Kocisko, Richard E. Race, Jiancao Chen, and Byron Caughey. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. 18th International Conference on Antiviral Research. April 10-14, 2005.


  26. John D. Morrey, Potential antiviral compounds. NIAID Workshop: Research on Control of Arboviral Encephalitides. May 19-20, 2004, Bethesda, MD.


  27. John D. Morrey, Anthony, L.S.D., Winslow, S.G., Liu, H., Rowse, G., Wu, B., Recktenwald, A., Julander, J.G., Mizzen, L.A., and Siegel, M.I. Immunization with Hsp65-HBV core antigen fusion protein overcomes immunological hyporesponsiveness in HBV transgenic mice. Frontiers in Drug Development for Viral Hepatitis, December 14 - 18, 2003, Kauai, Hawaii.


  28. John D. Morrey, C.W. Day, R.W. Sidwell. Murine and hamster therapeutic models for West Nile virus infection. ASM Biodefense Research Conference, March 9-12, 2003, Baltimore, Maryland, USA


  29. Morrey, J.D, R.P. Iyer, A. Roland, Y. Jin, , S. Mounir, J. D. Morrey. Dinucleotides as novel class of anti-hepatitis B virus agents: Evaluation of ORI-9020 in a transgenic mouse model. International Conference on Antiviral Research. April 27-May 1, 2003, Savannah, Georgia, USA.


  30. John D. Morrey, C.W. Day, R.W. Sidwell. Evaluation of therpeutics against West Nile virus in a hamster model. International Conference on Antiviral Research. April 27-May 1, 2003, Savannah, Georgia, USA.


  31. Day, C.W., John D. Morrey, R.W. Sidwell. Ribavirin efficacy against West Nile virus after multiple passages in cell culture. International Conference on Antiviral Research. April 27-May 1, 2003, Savannah, Georgia, USA.


  32. Blatt, L.M., H. Tan, J. Hong, J. Derrick, C. Day, John D. Morrey, M. Gross, C. Sanda, M. Taylor. Synergistic effects of type I (Infergen) and type 2 (Actimmune) interferons in preclinical models of HCV: Demonstration of potential efficacy. 54th Annual Meeting of the American Association for the Study of Liver Diseases. October 24-28, 2003, Boston, MA.


  33. Clark, J.L., C.J. Mason, S.E. Patterson, L.J. Stuyver, John D. Morrey, M.J. Otto, K.W. Pankiewicz, Mycophenolic acid analogues as potential agents against West Nile virus infection. 226th ACS National Meeting, New York, NY, September 7-11, 2003.


  34. Anthony, L.S.D., S.G. Winslow, H. Lui, G. Rowse, B. Wu, A. Recktenwald, L.A. Mizzen, John D. Morrey, M.I. Siegel. An Hsp65-HBV core antigen fusion protein primes HBcAg-specific CTL responses in immunologically tolerant HBV transgenic mice. 6th Annual Conference on Vaccine Research, 2003.


  35. John D. Morrey, Contractor's meeting for "Animal models evaluation of candidate hepatitis therapies." Oral presentation. May 2003, Rockville, Maryland.


  36. John D. Morrey, Contractor's meeting for "Animal models evaluation of candidate hepatitis therapies." Oral presentation. May 2003, Rockville, Maryland.


  37. John D. Morrey. Contractor's meeting for "Animal models of human viral infections for evaluation of experimental therapies." Oral presentation. May 2003, Rockville, Maryland.


  38. John D. Morrey. Contractor's meeting for "Animal models evaluation of candidate hepatitis therapies." Oral presentation. November 2003, Rockville, Maryland.


  39. John D. Morrey. NIH Contractor Meeting. HBV transgenic mouse model, Enteric and Hepatic Diseases Branch, DMID/NIAID/NIH, Washington, D.C., May 1999.


  40. Sidwell, R.W., Bailey, K.W., Bemis, P.A., Korba, B. E., John D. Morrey. Effect of interferon-alpha B/D treatment on viral parameters in transgenic mice replicating high levels of hepatitis B virus. 12th International Conference on Antiviral Research, Jerusalem, Israel, March 21-26, 1999.


  41. John D. Morrey, Korba, B.E., Sidwell, R.W. HBV transgenic mice as a chemotherapeutic model for HBV infection. IBC’s 5th Annual Conference on Hepatitis: Latest therapeutic developments for hepatitis B and C, St. Pete Beach, Florida, January 25-26, 1999.


  42. John D. Morrey. NIH Contractor Meeting. HBV transgenic mouse model, Enteric and Hepatic Diseases Branch, DMID/NIAID/NIH, Washington, D.C., May 1998.


  43. Thonabulsombat, S., Reed, W.A., White, K.L., John D. Morrey, Wang, L. 1998. Transgenic mice carrying a gene for green fluorescent protein fused to lytic peptide shiva 1 under control of the bovine b-casein regulatory region. Mol. Biol. Cell 9:1842.


  44. Mitalipov, S.M., John D. Morrey, Reed, W.A., White, K.L. 1998. Development of nuclear transfer and parthenogenetic rabbit embryos activated with inositol 1,4,5-triphosphate. Theriogenology 49:324.


  45. John D. Morrey. Universidad de La Salle, "Transgenic animal models for infectious human diseases", International Symposium on Reproduction - XXI Century, Bogota, Colombia, March 13, 1998.


  46. John D. Morrey. HBV transgenic mice as a chemotherapeutic model for HBV infection, Second International Conference on Therapies for Viral Hepatitis, Kona, Hawaii, December 15-19, 1997.


  47. John D. Morrey. NIH Contractor Meeting. HBV transgenic mouse model, Enteric and Hepatic Diseases Branch, DMID/NIAID/NIH, Washington, D.C., June 16, 1997.


  48. Bates, K., John D. Morrey, Reed, W.A., Thonabulsombat, C., White, K.L. 1996. Protein expression in milk of transgenic animals. Mol. Biol. Cell 7(S):2738.


  49. John D. Morrey. HIV and the molecular induction of virus, American Society for Photobiology, Scottsdale, AZ, June 25-29, 1994. (Invited speaker)


  50. John D. Morrey. Roche Molecular Systems, topic of "Regulation of HIV-1 LTR in Transgenic Mice", San Francisco, California, December 1993. (Invited speaker)


  51. Sidwell, R. W., John D. Morrey, Warren, R. P. The potential of cytokines as antiviral agents. Second International Congress on Biological Response Modifiers, San Diego, California, January 29-31, 1993.


  52. John D. Morrey, Sidwell, R.W., Yarosh, D. Efficacy studies of vitamin E using an HIV transgenic model. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 1993.


  53. Yarosh, D. Alas, L. Kibitel, J. O'Connor, A., Klein, J., John D. Morrey. Inhibition of HIV activation by UV in human cells and transgenic mice by topical application of DNA repair or antioxidant liposomes. 21st Annual Meeting of the American Society for Photobiology, Chicago, IL, June 1993.


  54. John D. Morrey, Murine models for AIDS. American Association for the Advancement of Science (AAAS), The University of Montana, Missoula, MT, June 22 1993. (Invited Plenary Speaker)


  55. Yarosh, D., Alas, L., Kibhel, J., O'Connor, A., Klein, J., John D. Morrey. Inhibition of HIV activation by UV in human cells and transgenic mice with DNA repair and antioxidant liposomes. Society of Investigative Dermatology, Washington, D.C., March 28-April 1, 1993.


  56. Sidwell, R. W., John D. Morrey, Warren, R. P. The potential of cytokines as antiviral agents. Second International Congress on Biological Response Modifiers, San Diego, California, January 29-31, 1993.


  57. Sidwell, R. W., Warren, R. P., Okleberry, K. M., Burger, R. A., John D. Morrey. Immunomodulators as antiviral agents. The New York Academy of Sciences, New York, May 1992.


  58. John D. Morrey, Bourn, S. M., Jackson, M. K., Bunch, T. D., Sidwell, R. W., Barrows, L. R., Daynes, R. A., Rosen, C. A. Transgenic mice as models for photo-induced gene expression: Activation of human immunodeficiency virus long terminal repeat. 20th Annual Meeting of the American Society for Photobiology, Marco Island, Florida, June 20-24, 1992.


  59. John D. Morrey. Transgenic disease models for Human Immunodeficiency Virus. Transgenic Disease Models Meeting of International Business Communications, San Diego, California, February 26-27, 1992.


  60. Sidwell, R. W., Okleberry, K. M., Burger, R. A., John D. Morrey. Suppression of murine retroviral disease as a model for AIDS by 2',3'-dideoxy-2',3'-didehydrothymidine (D4T). 5th International Conference on Antiviral Research, Vancouver, BC, Canada, March 8-13, 1992.


  61. John D. Morrey, Bunch, T. D., Bourn, S., Johnson, D., Sidwell, R. W., Rosen, C. A. Validation of a transgenic mouse model carrying HIV-1 LTR/firefly luciferase as a model for activation of HIV infection. Fourth International Conference of the National Cooperative Drug Discovery Groups, "Frontiers in HIV Therapy", San Diego, CA, November 3-7, 1991.


  62. John D. Morrey, Bourn, S. M., Bunch, T. D., Sidwell, R W., Barrows, L. R., Daynes, R. A., Rosen, C. A. In vivo activation of HIV-1 long terminal repeat by UV-B, psoralen-dependent UV-A irradiation and various skin applicants in transgenic mice. UCLA Symposium, Tamarron, CO, January 12-18, 1991.


  63. Sidwell, R. W., Mead, J. R., Warren, R. P., Okleberry, K. M., Burger, R. A., John D. Morrey. Elucidating mode of actions of biological response modifiers using immune competent and severe combined immune deficiency (SCID) mice infected with retrovirus. Fourth International Conference of the National Cooperative Drug Discovery Groups, "Frontiers in HIV Therapy", San Diego, CA, November 3-7, 1991.


  64. Morris, J. L. B., Barnard, D. L., Udy, K. J., Sidwell, R. W., John D. Morrey. Transgenic mice as a model for human immunodeficiency virus type-1 activation. American Association for Laboratory Animal Science (AALAS) Western Regional (District 8) Meeting Abstract, Salt Lake City, Utah, April 13-17, 1991


  65. Sidwell, R. W., Okleberry, K. J., Burger, R. A., Warren, R. P., John D. Morrey. Suppression of murine retroviral disease as a model for AIDS by 2',3'-dideoxy-2',3'-didehydrothymidine (D4T). International Conference on Antiviral Research, New Orleans, LA, April, 1991.


  66. Sidwell, R. W., Okleberry, K., Warren, R. P., Burger, R., Mead, J., John D. Morrey. Experiences with biological response modifiers in animal models in AIDS. International Congress of Chemotherapy, Berlin, June 1991.


  67. John D. Morrey, Warren, R.P., Okleberry, K.M., Burger, R.A., Sidwell, R.W., Chirigos, M.A., Johnston, M.I. Genetically-defined mice infected with Friend virus complex as a model for HIV infection: Effects of imexon treatment. American Society for Virology, University of Utah, Salt Lake City, UT, July 1990.


  68. John D. Morrey, Bunch, T. D., Jackson, M. K., Bourn, S., Jensen, S., Sidwell, R. W., Rosen, C. A. In vivo activation of HIV LTR in transgenic mice using firefly luciferase and beta-galactosidase reporter genes. RNA Tumor Viruses, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, May 1990.


  69. John D. Morrey, Bunch, T. D., Jackson, M. K., Bourn, S., Jensen, S., Shi, L. H., Sidwell, R. W., Rosen, C. A. HIV LTR linked to firefly luciferase and beta-galactosidase reporter genes in transgenic mice for evaluating treatments for HIV infection. Conference on Advances in Molecular Biology and Targeted Treatments for AIDS, Annual Meeting of the NIH National Cooperative Drug Discovery Groups for the Treatment of AIDS, The George Washington University, Washington, D. C. May 1990.


  70. John D. Morrey, Bunch, T. D., Jackson, M. K., Bourn, S., Jensen, S., Shi, L. H., Sidwell, R. W., Rosen, C. A. Comparison of genetically-defined strains of retrovirus-infected mice for evaluating mechanisms of action of biological response modifiers considered for the treatment of HIV infection. Conference on Advances in Molecular Biology and Targeted Treatments for AIDS, Annual Meeting of the NIH National Cooperative Drug Discovery Groups for the Treatment of AIDS, The George Washington University, Washington, D. C. May 1990.


  71. John D. Morrey, Warren, R. P., Okleberry, K. M., Burger, R. A., Johnston, M. I., Sidwell, R. W. A mouse genetics model for evaluation of biological response modifiers for the treatment of retroviral infection. Animal Models of Human Viral Diseases: Relevance to Developmental Therapeutics, UCLA Symposium, Keystone, CO, March 1990.


  72. Sidwell, R. W., John D. Morrey. Effects of imexon on Friend virus complex in genetically defined mice. Oral presentation, Division of AIDS NIH Subcommittee on BRMs, Bethesda, MD, January, 1990.


  73. Sidwell, R. W., John D. Morrey, Okleberry, K.D., Warren, R.D., Burger, R.A., Johnston, M.I. 1990. A comparison of immunomodulator effects on infections induced by the Friend retroviral complex in genetically defined mice. Intl. Conf. on Antiviral Research, Brussels, Belgium, April 1990.


  74. John D. Morrey, Knapp, G., Bourn, S., Bunch, T., Sidwell, R. W. Potential application of transgenic mice carrying human immunodeficiency virus sequences as models for evaluating therapeutic oligonucleotides or catalytic RNA. Conference on Oligonucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications, Rockville, MD, June 1989.


  75. John D. Morrey. Potential application of transgenic mice carrying human immunodeficiency virus sequences as models for evaluating therapeutic oligonucleotides or catalytic RNA. Invited oral presentation, Conference on Oligonucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications, Rockville, MD, June 1989.


  76. John D. Morrey, Warren, R. P., Okleberry, K. M., Burger, R. A., Sidwell, R. W. Effect of imexon on Friend virus complex infection in Rfv-3r/s genotype-containing mice as a model for AIDS. Second International Conference on Drug Research in Immunologic and Infectious Diseases: Acquired Immune Deficiency Syndrome (AIDS), Arlington, VA, November 1989.


  77. Warren, R. P., John D. Morrey, Burger, R. A., Okleberry, K. M., Sidwell, R. W. Murine retroviral disease enhancing effects of a pyrimidinone immunomodulator. American Society for Pharmacology and Experimental Therapeutics, Salt Lake City, Utah, August 1989.


  78. Sidwell, R. W., John D. Morrey, Warren, R. P., Okleberry, K., Burger, R., Johnston, M.I. Chemotherapy studies using the Friend retrovirus complex in Rfv-3r/s genotype-containing mice as a model for AIDS. International Symposium on Antiviral Chemotherapy, Porto Cervo, Sardinia, Italy, October 1989.


  79. John D. Morrey, Warren, R. P., Burger, R. A., Okleberry, K. M., Sidwell, R. W. Evaluation of biological response modifiers in a novel murine retrovirus model. Animal Models in AIDS, Maastricht, The Netherlands, October 1989.


  80. John D. Morrey, Warren, R. P., Okleberry, K. M., Burger, R. A., Sidwell, R. W. Effect of maleic anhydride-divinyl ether on Friend virus complex infection in Rfv-3r/s genotype-containing mice as a model for AIDS. Animal Models in AIDS, Maastricht, The Netherlands, October 1989.


  81. John D. Morrey. Friend virus complex infection in Rfv-3r/s genotype-containing mice as a model for HIV infection. Oral presentation, Development of cytokines for the treatment of AIDS, NIH AIDS National Cooperative Drug Discovery and Development Meeting, Baltimore, MD, July 1988.


  82. John D. Morrey. Evaluation of Biological Response Modifiers and Antivirals for AIDS Using Animal Models. Oral presentation, NIH AIDS Program Contractor's Meeting, Bethesda, MD, August 1988.


  83. John D. Morrey, Warren, R. P., Burger, R. A., Sidwell, R. W. Evaluation of biological response modifiers in a novel murine retrovirus model. NIH AIDS National Cooperative Drug Discovery Conference, Oakland, CA, October 1988.


  84. Burger, R. A., Warren, R. P., John D. Morrey, Okleberry, K. M., Sidwell, R. W. Therapeutic model for acquired immune deficiency syndrome. Clinical Immunology Symposium, San Francisco, CA, November 1988.